Protein Identified That Boosts Brain Tumor Resistance to Chemotherapy
By LabMedica International staff writers Posted on 26 Jan 2016 |

Image: Space-filling model of the anticancer drug temozolomide (Photo courtesy of Wikimedia Commons).
Cancer researchers have linked development of resistance to the anticancer drug temozolomide by glioblastoma multiforme (GBM) brain cancer cells to the activity of the RhoG-specific guanine nucleotide exchange factor protein SGEF.
GBM is the highest grade and most common form of primary adult brain tumors. Despite surgical removal followed by concomitant radiation and chemotherapy with the alkylating agent temozolomide (TMZ), GBM tumors develop treatment resistance and ultimately recur. Impaired response to treatment occurs rapidly, conferring a median survival of just fifteen months. Thus, researchers are seeking to identify the genetic and signaling mechanisms that promote tumor resistance in order to develop targeted therapies to combat this refractory disease.
The therapeutic benefit of TMZ depends on its ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. This methylation damages the DNA and triggers the death of tumor cells. However, some tumor cells are able to repair this type of DNA damage, and therefore diminish the therapeutic efficacy of TMZ, by expressing the protein O6-alkylguanine DNA alkyltransferase (AGT) encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. In some tumors, epigenetic silencing of the MGMT gene prevents the synthesis of this enzyme, and as a consequence such tumors are more sensitive to killing by TMZ. Conversely, the presence of AGT protein in brain tumors predicts poor response to TMZ and these patients receive little benefit from chemotherapy with this drug.
Previous studies have shown that SGEF (Src homology 3 domain-containing guanine nucleotide exchange factor) was overexpressed in GBM tumors and played a role in promoting TWEAK-Fn14–mediated glioma invasion. TWEAK is a multifunctional cytokine that controls many cellular activities including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. TWEAK acts by binding to Fn14, a highly inducible cell-surface receptor that is linked to several intracellular signaling pathways, including the nuclear factor-kappaB (NF-kappaB) pathway. The TWEAK–Fn14 axis normally regulates various physiological processes; in particular it seems to play an important, beneficial role in tissue repair following acute injury. Furthermore, recent studies have indicated that TWEAK–Fn14 axis signaling may contribute to cancer, chronic autoimmune diseases, and acute ischemic stroke.
Investigators at The Translational Genomics Research Institute (Phoenix, AZ, USA) reported in the January 13, 2016, online edition of the journal Molecular Cancer Research that SGEF expression was upregulated by TWEAK-Fn14 signaling via NF-kappaB activity while shRNA (short hairpin RNA)-mediated reduction of SGEF expression sensitized glioma cells to temozolomide-induced apoptosis and suppressed colony formation following temozolomide treatment.
Nuclear SGEF was activated following temozolomide exposure and formed complexes with the DNA damage repair protein BRCA1 (breast cancer 1), which enabled tumor cells to rapidly repair the damaged DNA that otherwise would lead to cell death. In contrast, BRCA1 phosphorylation in response to temozolomide treatment was hindered by inhibition of SGEF.
"We need to identify the genetic and cellular-pathway signaling mechanisms that make brain tumors resistant to treatment," said senior author Dr. Nhan Tran, head of the central nervous system tumor research laboratory at The Translational Genomics Research Institute. "And the role of SGEF in promoting chemotherapeutic resistance highlights this previously unappreciated protein. Importantly, this also suggests that SGEF could be a new candidate for development of targeted therapeutics."
Related Links:
The Translational Genomics Research Institute
GBM is the highest grade and most common form of primary adult brain tumors. Despite surgical removal followed by concomitant radiation and chemotherapy with the alkylating agent temozolomide (TMZ), GBM tumors develop treatment resistance and ultimately recur. Impaired response to treatment occurs rapidly, conferring a median survival of just fifteen months. Thus, researchers are seeking to identify the genetic and signaling mechanisms that promote tumor resistance in order to develop targeted therapies to combat this refractory disease.
The therapeutic benefit of TMZ depends on its ability to alkylate/methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues. This methylation damages the DNA and triggers the death of tumor cells. However, some tumor cells are able to repair this type of DNA damage, and therefore diminish the therapeutic efficacy of TMZ, by expressing the protein O6-alkylguanine DNA alkyltransferase (AGT) encoded in humans by the O-6-methylguanine-DNA methyltransferase (MGMT) gene. In some tumors, epigenetic silencing of the MGMT gene prevents the synthesis of this enzyme, and as a consequence such tumors are more sensitive to killing by TMZ. Conversely, the presence of AGT protein in brain tumors predicts poor response to TMZ and these patients receive little benefit from chemotherapy with this drug.
Previous studies have shown that SGEF (Src homology 3 domain-containing guanine nucleotide exchange factor) was overexpressed in GBM tumors and played a role in promoting TWEAK-Fn14–mediated glioma invasion. TWEAK is a multifunctional cytokine that controls many cellular activities including proliferation, migration, differentiation, apoptosis, angiogenesis, and inflammation. TWEAK acts by binding to Fn14, a highly inducible cell-surface receptor that is linked to several intracellular signaling pathways, including the nuclear factor-kappaB (NF-kappaB) pathway. The TWEAK–Fn14 axis normally regulates various physiological processes; in particular it seems to play an important, beneficial role in tissue repair following acute injury. Furthermore, recent studies have indicated that TWEAK–Fn14 axis signaling may contribute to cancer, chronic autoimmune diseases, and acute ischemic stroke.
Investigators at The Translational Genomics Research Institute (Phoenix, AZ, USA) reported in the January 13, 2016, online edition of the journal Molecular Cancer Research that SGEF expression was upregulated by TWEAK-Fn14 signaling via NF-kappaB activity while shRNA (short hairpin RNA)-mediated reduction of SGEF expression sensitized glioma cells to temozolomide-induced apoptosis and suppressed colony formation following temozolomide treatment.
Nuclear SGEF was activated following temozolomide exposure and formed complexes with the DNA damage repair protein BRCA1 (breast cancer 1), which enabled tumor cells to rapidly repair the damaged DNA that otherwise would lead to cell death. In contrast, BRCA1 phosphorylation in response to temozolomide treatment was hindered by inhibition of SGEF.
"We need to identify the genetic and cellular-pathway signaling mechanisms that make brain tumors resistant to treatment," said senior author Dr. Nhan Tran, head of the central nervous system tumor research laboratory at The Translational Genomics Research Institute. "And the role of SGEF in promoting chemotherapeutic resistance highlights this previously unappreciated protein. Importantly, this also suggests that SGEF could be a new candidate for development of targeted therapeutics."
Related Links:
The Translational Genomics Research Institute
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
Simple DNA PCR-Based Lab Test to Enable Personalized Treatment of Bacterial Vaginosis
Approximately one in three women aged 14-49 in the United States will experience bacterial vaginosis (BV), a vaginal bacterial imbalance, at some point in their lives. Around 50% of BV cases do not present... Read more
Rapid Diagnostic Test to Halt Mother-To-Child Hepatitis B Transmission
Hepatitis B, an inflammation of the liver caused by the hepatitis B virus (HBV), is the second-leading infectious cause of death globally, following tuberculosis. This viral infection can result in serious... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read moreCerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
In recent years, cancer immunotherapy has emerged as a promising approach where the patient's immune system is harnessed to fight cancer. One form of immunotherapy, called CAR-T-cell therapy, involves... Read more
New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more
Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read moreMicrobiology
view channel
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read moreInnovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
Each year, 11 million people across the world die of sepsis out of which 1.3 million deaths are due to antibiotic-resistant bacteria. The burden of antimicrobial resistance (AMR) continues to weigh heavily,... Read more
Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
Acute infectious gastroenteritis results in approximately 179 million cases each year in the United States, leading to a significant number of outpatient visits and hospitalizations. To address this, a... Read morePathology
view channel
New AI Model Predicts Gene Variants’ Effects on Specific Diseases
In recent years, artificial intelligence (AI) has greatly enhanced our ability to identify a vast number of genetic variants in increasingly larger populations. However, up to half of these variants are... Read more
Powerful AI Tool Diagnoses Coeliac Disease from Biopsy Images with Over 97% Accuracy
Coeliac disease is an autoimmune disorder triggered by the consumption of gluten, causing symptoms such as stomach cramps, diarrhea, skin rashes, weight loss, fatigue, and anemia. Due to the wide variation... Read moreTechnology
view channel
Smartphones Could Diagnose Diseases Using Infrared Scans
Rapid advancements in technology may soon make it possible for individuals to bypass invasive medical procedures by simply uploading a screenshot of their lab results from their phone directly to their doctor.... Read more
Novel Sensor Technology to Enable Early Diagnoses of Metabolic and Cardiovascular Disorders
Metabolites are critical compounds that fuel life's essential functions, playing a key role in producing energy, regulating cellular activities, and maintaining the balance of bodily systems.... Read more
3D Printing Breakthrough Enables Large Scale Development of Tiny Microfluidic Devices
Microfluidic devices are diagnostic systems capable of analyzing small volumes of materials with precision and speed. These devices are used in a variety of applications, including cancer cell analysis,... Read moreIndustry
view channel
Philips and Ibex Expand Partnership to Enhance AI-Enabled Pathology Workflows
Royal Philips (Amsterdam, The Netherlands) has expanded its partnership with Ibex Medical Analytics (Tel Aviv, Israel) and released the new Philips IntelliSite Pathology Solution (PIPS) to further accelerate... Read more
Grifols and Inpeco Partner to Deliver Transfusion Medicine ‘Lab of The Future’
Grifols (Barcelona, Spain), a manufacturer of plasma-derived medicines and innovative diagnostic solutions, has entered into a strategic agreement with Inpeco (Novazzano, Switzerland), a global leader... Read more